3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
4
Completed
2
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
3
Urinary Bladder Neoplasms
2
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Carcinoma in Situ
1
Interventions
Gemcitabine
2
rucaparib
1
pembrolizumab
1
enfortumab vedotin
1
Standard of Care
1
LHRH, lysine(6)-doxorubicin
1
Crizotinib
1
Cisplatin
1
Carboplatin
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Ureteral Neoplasms
×
enfortumab vedotin
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA